Tachyon Therapeutics

Tachyon Therapeutics is a biotechnology company focused on developing small molecule drugs for the treatment of cancer. The company’s research is centered on identifying and targeting novel mechanisms of tumorigenesis, which are the processes that lead to the formation and growth of tumors. 

The company has two main drug candidates in the pipeline: 1) TACH101, which targets the histone demethylase inhibitor to treat solid tumors, and, as of July 2023, was in a Phase I clinical study, and 2) TACH204 ( co-developed with AbCellera Biologics Inc ), which targets the LEFTY1 inhibitor to treat solid tumors and was in the discovery stage. In August 2022, the company received its Investigational New Drug application for TACH101, and it was the first KDM4 inhibitor to enter clinical study. 

Key customers and partnerships

In August 2021, the company partnered with AbCellera to develop TACH204 that targets the LEFTY1 antibody. 

Funding and financials

In March 2023, the company raised USD 11.6 million via an equity funding round , with participation from existing investors. The funds were used toward conducting Phase I clinical trials of TACH101 and to progress the company’s lineup of novel oncology drug candidates.